Insider Selling: Definium Therapeutics (NASDAQ:DFTX) Insider Sells $129,101.01 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Matthew Wiley sold 2,867 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares in the company, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Definium Therapeutics Stock Up 0.4%

Shares of Definium Therapeutics stock traded up $0.16 on Friday, reaching $44.95. 12,204,997 shares of the company were exchanged, compared to its average volume of 2,289,586. Definium Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.01. The company has a market cap of $4.48 billion, a P/E ratio of -18.05 and a beta of 2.37. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The stock’s 50 day moving average price is $24.13 and its 200-day moving average price is $19.18.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, equities analysts forecast that Definium Therapeutics, Inc. will post -2.29 EPS for the current year.

Institutional Trading of Definium Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC lifted its position in shares of Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after buying an additional 1,165 shares during the last quarter. Creative Planning grew its position in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after buying an additional 1,655 shares during the last quarter. Rathbones Group PLC grew its position in shares of Definium Therapeutics by 7.1% in the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock valued at $356,000 after buying an additional 2,000 shares during the last quarter. Bay Rivers Group raised its stake in Definium Therapeutics by 14.3% during the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares in the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. HC Wainwright raised their price objective on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday. Oppenheimer set a $60.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a report on Monday. JonesTrading raised their price target on Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $47.08.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.